% | $
Quotes you view appear here for quick access.

Supernus Pharmaceuticals, Inc. (SUPN) Message Board

  • downtolastdollar downtolastdollar May 3, 2013 6:35 PM Flag


    Does any of SUPN product has anything new in them? These are all old medicine/salts that are somebody elses and long discarded. What is SUPN trying to do? No wonder nothing is selling.

    This is from the SUPN website:

    SPN-810 (molindone hydrochloride)

    Previously marketed in the United States to treat schizophrenia under the trade name Moban®, molindone hydrochloride.In addition, the lower doses tested for the proposed indication of impulsive aggression may be better tolerated than the higher doses approved to treat schizophrenia.

    Molindone was discontinued by its sole supplier, Endo Pharmaceuticals, on January 13, 2010.


    While the active ingredient in SPN-812 has an extensive safety record in Europe, where it was marketed for many years as an antidepressant, SPN-812 could provide an additional option to the few nonstimulant therapies currently available.


    SPN-809 is based on the same active ingredient that is in SPN-812. The active ingredient in SPN-809 was approved and marketed for depression in Europe for many years.

    Similarly, Oxtellar XR™ delivers oxcarbazepine, an effective antiepileptic drug, which is marketed by Novartis Pharmaceuticals Corporation under the brand name Trileptal®.

    Is this company a total scam? The management seems like just keep on raising money and spending it like there is no tomorrow.


    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • That's what I think is a great story for SUPN. They don't have the R&D or trial expenses to develop a new drug. Instead, they take existing drugs, with proven track records, add a proprietary time release element to the drug to improve them and sell that. They also test drugs used for one purpose for other purposes which is not so uncommon in the drug industry. Some companies don't drop drugs because they were unsuccessful but because their exclusive rights to market them expire and therefore the profits so they stop marketing it by a brand name but may manufacture it as a generic instead.

22.07+0.72(+3.37%)Aug 26 4:00 PMEDT